产品
编 号：F351418
分子式：C18H19N3O2S
分子量：341.43
分子式：C18H19N3O2S
分子量：341.43
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
结构图
CAS No: 409351-28-6
产品详情
生物活性：
VU0152100 (VU152100) is a highly selective mAChR positive allosteric modulator (permeable to the blood-brain barrier). VU0152100 reverses Amphetamine-induced hypermotility in rats and increased levels of extracellular dopamine in nucleus accumbens and caudate-putamen. VU0152100 has good research potential in psychosis and cognitive impairment associated with mental disorders such as schizophrenia.
体内研究：
VU0152100 (10, 30, 56.6 mg/kg; i.p; single) 逆转安非他命诱导的大鼠过度运动。VU0152100 (10, 30, 56.6 mg/kg; i.p.; single) 阻断安非他明诱导的对大鼠获得情境性恐惧调节和声学惊吓反射的前脉冲抑制的干扰。VU0152100 能逆转安非他明诱导的伏隔核和尾状核-壳核中细胞外多巴胺水平的增加。Animal Model:Adult male Sprague-Dawley rats (250-275 g; amphetamine-induced hyperlocomotion model).
Dosage:10, 30, 56.6 mg/kg
Administration:Intraperitoneal injection; single (pre-treatment)
Result:Produced a robust dose-dependent reversal of amphetamine-induced hyperlocomotion.
Animal Model:Adult male Sprague-Dawley rats (250-275 g; amphetamine-induced).
Dosage:10, 30, 56.6 mg/kg
Administration:Intraperitoneal injection; single (pre-treatment)
Result:Blocked amphetamine-induced disruption of prepulse inhibition.Dose-dependently reversed the disruptive effects of amphetamine on the acquisition of a context-dependent fear.
VU0152100 (VU152100) is a highly selective mAChR positive allosteric modulator (permeable to the blood-brain barrier). VU0152100 reverses Amphetamine-induced hypermotility in rats and increased levels of extracellular dopamine in nucleus accumbens and caudate-putamen. VU0152100 has good research potential in psychosis and cognitive impairment associated with mental disorders such as schizophrenia.
体内研究：
VU0152100 (10, 30, 56.6 mg/kg; i.p; single) 逆转安非他命诱导的大鼠过度运动。VU0152100 (10, 30, 56.6 mg/kg; i.p.; single) 阻断安非他明诱导的对大鼠获得情境性恐惧调节和声学惊吓反射的前脉冲抑制的干扰。VU0152100 能逆转安非他明诱导的伏隔核和尾状核-壳核中细胞外多巴胺水平的增加。Animal Model:Adult male Sprague-Dawley rats (250-275 g; amphetamine-induced hyperlocomotion model).
Dosage:10, 30, 56.6 mg/kg
Administration:Intraperitoneal injection; single (pre-treatment)
Result:Produced a robust dose-dependent reversal of amphetamine-induced hyperlocomotion.
Animal Model:Adult male Sprague-Dawley rats (250-275 g; amphetamine-induced).
Dosage:10, 30, 56.6 mg/kg
Administration:Intraperitoneal injection; single (pre-treatment)
Result:Blocked amphetamine-induced disruption of prepulse inhibition.Dose-dependently reversed the disruptive effects of amphetamine on the acquisition of a context-dependent fear.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备